G. Groenewegen

发表

A comparison of six software packages for evaluation of solid lung nodules using semi-automated volumetry: What is the minimum increase in size to detect growth in repeated CT examinations

B. Ginneken, H. Gietema, M. Prokop, 2009, European Radiology.

Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT-- influence of inspiration level, nodule size, and segmentation performance.

Mathias Prokop, H. Gietema, M. Prokop, 2007, Radiology.

The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions

G. Groenewegen, A. Griffioen, S. Martinotti, 2004, Angiogenesis.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

D. Rea, D. Richel, C. Punt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

H. Rosing, J. Beijnen, G. Groenewegen, 2004, British Journal of Cancer.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

J. Witjes, G. Groenewegen, F. V. van Leeuwen, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer

G. Groenewegen, R. Repp, J. V. D. van de Winkel, 1997, Cancer Immunology, Immunotherapy.

Lymphokines induce changes in morphology and enhance motility of endothelial cells.

G. Groenewegen, W. Buurman, C. J. van der Linden, 1985, Clinical immunology and immunopathology.

Supernatants of human leukocytes contain mediator, different from interferon gamma, which induces expression of MHC class II antigens

G. Groenewegen, W. Buurman, G. Jeunhomme, 1986, The Journal of experimental medicine.

Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.

G. Jayson, M. Ranson, G. Groenewegen, 2001 .

Lymphokine dependence of in vivo expression of MHC class II antigens by endothelium

G. Groenewegen, W. Buurman, C. Linden, 1985, Nature.

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.

G. Jayson, M. Ranson, G. Groenewegen, 2005, European journal of cancer.

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

G. Groenewegen, E. Voest, J. Haanen, 2012, British Journal of Cancer.

Donor-Derived Testicular Germ Cell Cancer in a Heart Transplant Recipient

L. V. Van Laake, G. Groenewegen, N. de Jonge, 2021, JACC. CardioOncology.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as ﬁrst-line therapy for advanced colorectal cancer

D. Kerr, D. Richel, G. Groenewegen, 2005 .

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

G. Groenewegen, S. Osanto, R. Jansen, 2000, British Journal of Cancer.

Vascular Endothelial Cells Present Alloantigens to Unprimed Lymphocytes

G. Groenewegen, W. Buurman, 1984, Scandinavian journal of immunology.

Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.

Terri Leahy, G. Groenewegen, E. Voest, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Class II antigens on canine T lymphocytes.

G. Groenewegen, W. Buurman, B. Schutte, 2008, Tissue antigens.

Cell-mediated cytotoxicity toward class I and class II antigens on canine T and B lymphoblasts.

G. Groenewegen, W. Buurman, G. Kootstra, 2008, Tissue antigens.

Cellular cytotoxicity against canine endothelial cells. Analysis of determinants recognized by CTL.

G. Groenewegen, W. Buurman, G. Kootstra, 2008, Tissue antigens.

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan : An Endothelin Receptor Antagonist for Refractory Prostate Cancer 1

Terri Leahy, G. Groenewegen, E. Voest, 2003 .

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

M. Kersten, G. Groenewegen, S. Horenblas, 2003, British Journal of Cancer.

Canine MHC-class II antigens on B and T lymphocytes.

G. Groenewegen, W. Buurman, C. J. van der Linden, 2008, Tissue antigens.

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

Wendy S. Becker, G. Groenewegen, M. Eisenhut, 2003, British Journal of Cancer.

Endoglin/CD 105 may not be an optimal tumor endothelial treatment target

G. Groenewegen, A. Griffioen, G. Blijham, 2005, Breast Cancer Research and Treatment.

Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer 1

G. Groenewegen, E. Voest, M. Los, 2010 .

Canine IL-2: characterization and optimal conditions for production.

G. Groenewegen, W. Buurman, G. Kootstra, 1984, Veterinary immunology and immunopathology.

Limiting dilution assays. Experimental design and statistical analysis.

W A Buurman, G. Groenewegen, L. Strijbosch, 1987, Journal of immunological methods.

Risk of diabetes after para-aortic radiation for testicular cancer

J. Witjes, G. Groenewegen, F. V. van Leeuwen, 2018, British Journal of Cancer.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial

S. Sleijfer, G. Groenewegen, E. Voest, 2017, JAMA oncology.

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.

G. Groenewegen, A. Griffioen, G. Blijham, 1996, Blood.

Analysis of buoyant density of canine peripheral blood leukocytes with PVP-Silica (Percoll) density gradients.

G. Groenewegen, W. Buurman, P. Vegt, 1982, Veterinary immunology and immunopathology.

Angiogenesis inhibitors overcome tumor induced endothelial cell anergy

G. Groenewegen, A. Griffioen, S. Martinotti, 1999, International journal of cancer.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

A. Eggermont, A. Testori, C. Punt, 2005, The Lancet.

Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.

G. Groenewegen, A. Griffioen, S. Martinotti, 1996, Cancer research.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

G. Hospers, G. Groenewegen, J. Haanen, 2017, European journal of cancer.

Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.

G. Groenewegen, J. Haanen, G. Vreugdenhil, 2020, Clinical genitourinary cancer.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

G. Hospers, G. Groenewegen, J. Haanen, 2018, Anti-cancer drugs.

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

G. Groenewegen, A. Bloem, G. D. de Gast, 2002, Cancer Immunology, Immunotherapy.

The decisive role of molecular pathology in presumed somatic metastases of type II testicular germ cell tumors: report of 2 cases

L. Looijenga, G. Groenewegen, G. Offerhaus, 2020, Diagnostic Pathology.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

J. Schellens, J. Beijnen, G. Groenewegen, 2002, Cancer Chemotherapy and Pharmacology.

[Interferon for adjuvant therapy in melanoma; although approved, not indicated].

C. Punt, G. Groenewegen, H. J. van der Rhee, 2000, Nederlandsch tijdschrift voor geneeskunde.

1067 Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III

A. Eggermont, A. Testori, C. Punt, 2003 .

CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells.

G. Groenewegen, A. Griffioen, G. Blijham, 1997, Blood.

Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells.

G. Groenewegen, W. Buurman, T. Ruers, 1986, Journal of Immunology.

Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.

F. Schramel, G. Groenewegen, E. Voest, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vascular endothelial cells in immune reactions

G. Groenewegen, 1985 .

Effect of culture conditions on endothelial cell growth and responsiveness.

G. Groenewegen, A. Griffioen, D. W. J. van der Schaft, 1998, Tissue & cell.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

S. Sleijfer, J. Schellens, J. Beijnen, 2010, Annals of Oncology.

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

Jamal Zweit, Manfred Herold, Gordon C Jayson, 2002, Journal of the National Cancer Institute.

Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors.

G. Groenewegen, A. Griffioen, G. Blijham, 1997, Cancer letters.

Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life

J. Witjes, G. Groenewegen, F. V. van Leeuwen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IN VITRO STIMULATION OF LYMPHOCYTES BY VASCULAR ENDOTHELIAL CELLS: A Study with Canine Arterial and Venous Endothelial Cells

G. Groenewegen, W. Buurman, G. Kootstra, 1984, Transplantation.

Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.

J. Witjes, J. Bosch, G. Groenewegen, 2020, Journal of Clinical Oncology.

Platinum exposure and cause‐specific mortality among patients with testicular cancer

J. Witjes, G. Groenewegen, F. V. van Leeuwen, 2019, Cancer.

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

G. Groenewegen, E. Voest, M. Los, 2010, Neoplasia.

Risk of diabetes after para-aortic radiation for testicular cancer

J. Witjes, G. Groenewegen, F. V. van Leeuwen, 2018, British Journal of Cancer.

Impact of integration of clinical and outpatient units on cancer patient satisfaction.

G. Groenewegen, P. Tjia, E. Voest, 2010, International journal for quality in health care : journal of the International Society for Quality in Health Care.

EFFECT OF CYCLOSPORINE ON MHC CLASS II ANTIGEN EXPRESSION ON ARTERIAL AND VENOUS ENDOTHELIUM IN VITRO

G. Groenewegen, W. Buurman, G. Jeunhomme, 1985, Transplantation.

A new lymphokine different from interferon-gamma induces major histocompatibility complex class II antigen expression.

G. Groenewegen, W. Buurman, G. Kootstra, 1987, Transplantation proceedings.

Impact of integration of clinical and outpatient units on cancer patient satisfaction.

G. Groenewegen, P. Tjia, E. Voest, 2010, International journal for quality in health care : journal of the International Society for Quality in Health Care.